Loading next page...
/lp/american-medical-association/underestimation-of-cutaneous-squamous-cell-carcinoma-incidence-even-in-A9QqxDTFT9
- Publisher
- American Medical Association
- Copyright
- Copyright 2020 American Medical Association. All Rights Reserved.
- ISSN
- 2168-6068
- eISSN
- 2168-6084
- DOI
- 10.1001/jamadermatol.2020.3678
- Publisher site
- See Article on Publisher Site
Abstract
Opinion Editorial options is under way. Even procedures as seemingly or more medications are labeled as allergies, limiting future straightforward as estimation of BSA involvement in EN therapeutic options. Combined in vivo and ex vivo testing (defined in SCORTEN as the sum of detached and detachable via patch testing and interferon-γ release assay, respec- epidermis ) are subject to interobserver variability depending tively, have been used safely in a pilot study to assign drug on the specific formula used and the extent of cutaneous causality with moderate sensitivity and high specificity. involvement. Similarly, while in-hospital mortality is an Further investigation is needed to devise a personalized objective, defined outcomes and proxy outcomes like time- approach to drug hypersensitivity testing and safe medica- to-reepithelization are often poorly defined or of uncertain tion prescribing among survivors of EN. significance as surrogate markers of treatment response. In conclusion, future clinical and translational research in Consistent terminology, rigorous disease metrics, and EN should focus on improving and standardizing prevention, meaningful, evidence-based outcomes are essential for diagnosis, and treatment options for patients. Multi- successful conduct of EN-related research around the world. institutional, international collaborations with standardized, Understanding and addressing the long-term physical and evidence-based
Journal
JAMA Dermatology – American Medical Association
Published: Dec 28, 2020